88 related articles for article (PubMed ID: 15374707)
1. Effect of hormone therapy and raloxifene on serum VE-cadherin in postmenopausal women.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Papadias C; Economou E; Creatsas G
Fertil Steril; 2004 Sep; 82(3):634-8. PubMed ID: 15374707
[TBL] [Abstract][Full Text] [Related]
2. The effect of hormone therapy and raloxifene on serum matrix metalloproteinase-2 and -9 in postmenopausal women.
Christodoulakos GE; Panoulis CP; Lambrinoudaki IV; Botsis DS; Dendrinos SG; Economou E; Creatsas GC
Menopause; 2004; 11(3):299-305. PubMed ID: 15167309
[TBL] [Abstract][Full Text] [Related]
3. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endothelin-1 synthesis.
Christodoulakos G; Panoulis C; Kouskouni E; Chondros C; Dendrinos S; Creatsas G
Gynecol Endocrinol; 2002 Feb; 16(1):9-17. PubMed ID: 11915588
[TBL] [Abstract][Full Text] [Related]
4. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women.
Christodoulakos GE; Lambrinoudaki IV; Creatsa MG; Economou EV; Siasou Z; Panoulis CP; Kalligerou I; Papadias C
Climacteric; 2008 Apr; 11(2):155-65. PubMed ID: 18365858
[TBL] [Abstract][Full Text] [Related]
5. A multicentre randomised trial to compare uterine safety of raloxifene with a continuous combined hormone replacement therapy containing oestradiol and norethisterone acetate.
Neven P; Lunde T; Benedetti-Panici P; Tiitinen A; Marinescu B; de Villiers T; Hillard T; Cano A; Peer E; Quail D; Nickelsen T;
BJOG; 2003 Feb; 110(2):157-67. PubMed ID: 12618160
[TBL] [Abstract][Full Text] [Related]
6. A microarray study on the effect of four hormone therapy regimens on gene transcription in whole blood from healthy postmenopausal women.
Dahm AE; Eilertsen AL; Goeman J; Olstad OK; Ovstebø R; Kierulf P; Mowinckel MC; Skretting G; Sandset PM
Thromb Res; 2012 Jul; 130(1):45-51. PubMed ID: 22217510
[TBL] [Abstract][Full Text] [Related]
7. Uterine effects of raloxifene in comparison with continuous-combined hormone replacement therapy in postmenopausal women.
Fugère P; Scheele WH; Shah A; Strack TR; Glant MD; Jolly E
Am J Obstet Gynecol; 2000 Mar; 182(3):568-74. PubMed ID: 10739509
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition.
Yüksel H; Odabaşi AR; Demircan S; Karul A; Kozaci LD; Köseoğlu K; Kizilkaya K; Başak O
Gynecol Endocrinol; 2006 Jul; 22(7):381-7. PubMed ID: 16864148
[TBL] [Abstract][Full Text] [Related]
9. Neither long-term treatment with raloxifene nor hormone replacement therapy modulate cardiac function in healthy postmenopausal women: two randomized, placebo-controlled, 2-year studies.
Vogelvang TE; Mijatovic V; Kamp O; Netelenbos JC; Neele SJ; Pines A; Kenemans P; van der Mooren MJ
Am J Obstet Gynecol; 2002 Apr; 186(4):729-36. PubMed ID: 11967499
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene reduces impedance to flow within the uterine artery in early postmenopausal women: a 2-year randomized, placebo-controlled, comparative study.
Post MS; van der Mooren MJ; van Baal WM; Neele SJ; Netelenbos JC; Kenemans P
Am J Obstet Gynecol; 2001 Sep; 185(3):557-62. PubMed ID: 11568777
[TBL] [Abstract][Full Text] [Related]
11. Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene.
Lambrinoudaki IV; Christodoulakos GE; Economou EV; Vlachou SA; Panoulis CP; Alexandrou AP; Kouskouni EE; Creatsas GC
Maturitas; 2008 Jan; 59(1):62-71. PubMed ID: 18164562
[TBL] [Abstract][Full Text] [Related]
12. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
[TBL] [Abstract][Full Text] [Related]
13. Raloxifene therapy in postmenopausal women is associated with a significant reduction in the concentration of serum vascular endothelial growth factor.
Lam PM; Yim SF; Briton-Jones C; Chung TK; Haines C
Fertil Steril; 2004 Feb; 81(2):393-7. PubMed ID: 14967379
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
[TBL] [Abstract][Full Text] [Related]
15. Low-dose hormone therapy and carbohydrate metabolism.
Li C; Samsioe G; Borgfeldt C; Bendahl PO; Wilawan K; Aberg A
Fertil Steril; 2003 Mar; 79(3):550-5. PubMed ID: 12620438
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study.
Nickelsen T; Creatsas G; Rechberger T; Depypere H; Erenus M; Quail D; Arndt T; Bonnar J;
Climacteric; 2001 Dec; 4(4):320-31. PubMed ID: 11770189
[TBL] [Abstract][Full Text] [Related]
17. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
Christodoulakos G; Lambrinoudaki I; Panoulis C; Sioulas V; Rizos D; Caramalis G; Botsis D; Creatsas G
Maturitas; 2005 Apr; 50(4):321-30. PubMed ID: 15780533
[TBL] [Abstract][Full Text] [Related]
18. Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene.
Christodoulakos GE; Lambrinoudaki IV; Economou EV; Papadias C; Vitoratos N; Panoulis CP; Kouskouni EE; Vlachou SA; Creatsas GC
Atherosclerosis; 2007 Jul; 193(1):142-50. PubMed ID: 16842799
[TBL] [Abstract][Full Text] [Related]
19. Endometrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women.
Davies GC; Huster WJ; Shen W; Mitlak B; Plouffe L; Shah A; Cohen FJ
Menopause; 1999; 6(3):188-95. PubMed ID: 10486787
[TBL] [Abstract][Full Text] [Related]
20. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women.
Mijatovic V; Netelenbos C; van der Mooren MJ; de Valk-de Roo GW; Jakobs C; Kenemans P
Fertil Steril; 1998 Dec; 70(6):1085-9. PubMed ID: 9848300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
